❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Cancer Genetics ❭ Translational studies on solid tumours [Helland] ❭ Clinical trials ❭ COM-IT-2 ❭

COM-IT-2 Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer

– a phase II randomised clinical and translational trial

  • EudraCT number: 2021-003266
Background/study objectives
Study design
Collaborative partners
Update/publications

Home Dept. of Cancer Genetics Translational studies on solid tumours [Helland]

  • Group members
  • Clinical trials
    • DART
    • NIPU
    • COM-IT-2
  • Translational studies
  • Publications
  • News

Recent publications

Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
New centres to carry out more clinical trials in Norway
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0722, PubMed 36718905

Børø S, Thoresen S, Helland Å (2022)
Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
Front Oncol, 12, 1017902
DOI 10.3389/fonc.2022.1017902, PubMed 36523970

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Front Oncol, 12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452



More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Email: trond.olav.berg@rr-research.no

Cookie policy

Accessibility statement (in Norwegian)